Pentech Ventures News Today

Biopharma companies are harnessing AI tools for multiple aspects of drug development such as identifying drug development targets, modeling a drug's effect on the body, and more.

The FTC’s antagonism of Big Tech sets companies up for “painfully long processes” for dealmaking, says Battery Ventures’s Chelsea Stoner.

Nvidia, Northwell Health and others saw an influx in digital health dollars this week.

Causality uses machine learning to automate the prior, heavily manual processes of biomedical research and drug discovery.

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

The round brings the company's total raise to $93 million.

The financing, led by ICONIQ Growth, enables Causaly to accelerate innovation and drive increased adoption of its category-leading AI platform to modernize scientific research.LONDON & SAN FRANCISCO--(BUSINESS WIRE)--Causaly, the leading AI platform for biomedical research, closed $60m in Series B funding led by ICO...

Artificial intelligence has been a big theme in the world of health and medical research, and specifically in the area of drug discovery. Causaly, a London startup that has built an AI platform to help researchers accelerate the development and testing of drugs, has raised $60 million, a Series B that will be going toward R&D and to continue building out its team. ICONIQ Growth -- the growth-stage fund affiliated with the iconic investment firm of the same name -- is leading the round, wi...

FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!

Deep Render, a startup developing AI-based methods of compressing videos, is participating in this year's Disrupt Battlefield 200.